Page 16 - Dr Stephanie Seneff - Reviewing Some Possible Unintended Consequences of the mRNA Vaccines Against COVID - 19

with cutaneous manifestations following symptomatic COVID-19. In one case a 39-year-old male
had SLE onset two months following outpatient treatment for COVID-19 (Zamani et.al., 2021).
Another striking case of rapidly progressing and fatal SLE with cutaneous manifestations is
described by Slimani et.al. (2021).

Autoantibodies are very commonly found in COVID-19 patients, including antibodies found in
blood (Vlachoyiannopoulos et. al., 2020) and cerebrospinal fluid (CFS) (Franke et. al., 2021).
Though SARS-CoV-2 is not found in the CSF, it is theorized that the autoantibodies created in
response to SARS-CoV-2 exposure may lead to at least some portion of the neurological
complications documented in COVID-19 patients. One important Letter to the Editor submitted to
the journal Arthritis & Rheumatology by Bertin et. al. (2020) noted the high prevalence and strong
association (p=0.009) of autoantibodies against cardiolipin in COVID-19 patients with severe
disease.

Zuo et. al. (2020) found anti-phospholipid autoantibodies in 52% of hospitalized COVID-19
patients and speculated that these antibodies contribute to the high incidence of coagulopathies in
these patients. Schiaffino et. al. (2020) reported that serum from a high percentage of hospitalized
COVID-19 patients contained autoantibodies reactive to the plasma membrane of hepatocytes and
gastric cells. One patient with Guillain-Barre Syndrome was found to have antibody reactivity in
cerebrospinal fluid (CFS), leading the authors to suggest that cross-reactivity with proteins in the
CFS could lead to neurological complications seen in some COVID-19 patients. In a more recent
review, Gao et. al. (2021) noted high levels of autoantibodies in COVID-19 patients across multiple
studies. They conclude, “[O]ne of the potential side effects of giving a mass vaccine could be an
mergence [sic] of autoimmune diseases especially in individuals who are genetically prone for
autoimmunity.”

A recent publication compiles a great deal of evidence that autoantibodies against a broad range of
receptors and tissue can be found in individuals who have had previous SARS-CoV-2 infection. “All
31 former COVID-19 patients had between 2 and 7 different GPCR-fAABs [G-protein coupled
receptor functional autoantibodies] that acted as receptor agonists.” (Wallukat et. al. 2021) The
diversity of GPCR-fAABs identified, encompassing both agonist and antagonist activity on target
receptors, strongly correlated with a range of post-COVID-19 symptoms, including tachycardia,
bradycardia, alopecia, attention deficit, PoTS, neuropathies, and others.

The same study, referencing the autoantibodies predicted by Lyons-Weiler (2020) mentioned above,
notes with obvious grave concern: “The Sars-CoV-2 spike protein is a potential epitopic target for
25
biomimicry-induced autoimmunological processes [ ]. Therefore, we feel it will be extremely
important to investigate whether GPCR-fAABs will also become detectable after immunisation by
vaccination against the virus.”

We have reviewed the evidence here that the spike protein of SARS-CoV-2 has extensive sequence
homology with multiple endogenous human proteins and could prime the immune system toward
development of both auto-inflammatory and autoimmune disease. This is particularly concerning
given that the protein has been redesigned with two extra proline residues to potentially impede its
clearance from the circulation through membrane fusion. These diseases could present acutely and

International Journal of Vaccine Theory, Practice, and Research 2(1), May 10, 2021 Page | 404